Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technol… Read more
Kuros Biosciences AG (CSBTF) - Net Assets
Latest net assets as of June 2025: $76.65 Million USD
Based on the latest financial reports, Kuros Biosciences AG (CSBTF) has net assets worth $76.65 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($109.97 Million) and total liabilities ($33.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $76.65 Million |
| % of Total Assets | 69.7% |
| Annual Growth Rate | -1.54% |
| 5-Year Change | -30.56% |
| 10-Year Change | 8681.46% |
| Growth Volatility | 1316.08 |
Kuros Biosciences AG - Net Assets Trend (2004–2024)
This chart illustrates how Kuros Biosciences AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kuros Biosciences AG (2004–2024)
The table below shows the annual net assets of Kuros Biosciences AG from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $58.75 Million | +3.59% |
| 2023-12-31 | $56.71 Million | -17.64% |
| 2022-12-31 | $68.86 Million | -10.54% |
| 2021-12-31 | $76.98 Million | -9.01% |
| 2020-12-31 | $84.60 Million | +8.66% |
| 2019-12-31 | $77.86 Million | +1.79% |
| 2018-12-31 | $76.48 Million | +4.57% |
| 2017-12-31 | $73.14 Million | +90.86% |
| 2016-12-31 | $38.32 Million | +5628.25% |
| 2015-12-31 | $669.00K | +102.55% |
| 2014-12-31 | $-26.22 Million | -719.86% |
| 2013-12-31 | $4.23 Million | -57.82% |
| 2012-12-31 | $10.03 Million | +185.86% |
| 2011-12-31 | $-11.68 Million | -277.10% |
| 2010-12-31 | $6.59 Million | -19.97% |
| 2009-12-31 | $8.24 Million | -74.13% |
| 2008-12-31 | $31.86 Million | -41.47% |
| 2007-12-31 | $54.43 Million | +18.59% |
| 2006-12-31 | $45.90 Million | -37.98% |
| 2005-12-31 | $74.01 Million | -7.69% |
| 2004-12-31 | $80.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kuros Biosciences AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4393700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.79 Million | 6.45% |
| Other Components | $100.39 Million | 170.88% |
| Total Equity | $58.75 Million | 100.00% |
Kuros Biosciences AG Competitors by Market Cap
The table below lists competitors of Kuros Biosciences AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank Islam Malaysia Bhd
KLSE:5258
|
$594.30 Million |
|
Borusan Yatirim ve Pazarlama AS
IS:BRYAT
|
$594.49 Million |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
$594.94 Million |
|
Shenzhen SEG Co Ltd
SHE:000058
|
$595.06 Million |
|
Elopak AS
OL:ELO
|
$593.96 Million |
|
AS LHV GROUP EO -10
F:ASU0
|
$593.91 Million |
|
Dom Development S.A.
WAR:DOM
|
$593.81 Million |
|
Konoike Transport Co. Ltd
F:2KT
|
$593.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kuros Biosciences AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 56,712,000 to 58,748,000, a change of 2,036,000 (3.6%).
- Net loss of 3,716,000 reduced equity.
- New share issuances of 1,941,000 increased equity.
- Other comprehensive income decreased equity by 21,886,000.
- Other factors increased equity by 25,697,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.72 Million | -6.33% |
| Share Issuances | $1.94 Million | +3.3% |
| Other Comprehensive Income | $-21.89 Million | -37.25% |
| Other Changes | $25.70 Million | +43.74% |
| Total Change | $- | 3.59% |
Book Value vs Market Value Analysis
This analysis compares Kuros Biosciences AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.67x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.01x to 12.67x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $1464.04 | $20.01 | x |
| 2005-12-31 | $1199.65 | $20.01 | x |
| 2006-12-31 | $720.67 | $20.01 | x |
| 2007-12-31 | $840.46 | $20.01 | x |
| 2008-12-31 | $488.78 | $20.01 | x |
| 2009-12-31 | $126.34 | $20.01 | x |
| 2010-12-31 | $101.09 | $20.01 | x |
| 2011-12-31 | $-179.01 | $20.01 | x |
| 2012-12-31 | $49.93 | $20.01 | x |
| 2013-12-31 | $14.63 | $20.01 | x |
| 2014-12-31 | $-74.52 | $20.01 | x |
| 2015-12-31 | $0.42 | $20.01 | x |
| 2016-12-31 | $6.19 | $20.01 | x |
| 2017-12-31 | $8.33 | $20.01 | x |
| 2018-12-31 | $7.47 | $20.01 | x |
| 2019-12-31 | $4.53 | $20.01 | x |
| 2020-12-31 | $3.48 | $20.01 | x |
| 2021-12-31 | $2.35 | $20.01 | x |
| 2022-12-31 | $2.03 | $20.01 | x |
| 2023-12-31 | $1.55 | $20.01 | x |
| 2024-12-31 | $1.58 | $20.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kuros Biosciences AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.92%
- • Asset Turnover: 0.89x
- • Equity Multiplier: 1.44x
- Recent ROE (-6.33%) is above the historical average (-29.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -29.75% | -580.01% | 0.05x | 1.10x | $-31.87 Million |
| 2005 | -38.48% | -653.51% | 0.05x | 1.11x | $-35.88 Million |
| 2006 | -75.28% | -4772.38% | 0.01x | 1.25x | $-39.14 Million |
| 2007 | -12.63% | -19.16% | 0.29x | 2.27x | $-12.32 Million |
| 2008 | -81.64% | -131.87% | 0.18x | 3.48x | $-29.20 Million |
| 2009 | -301.25% | -272.57% | 0.13x | 8.34x | $-25.65 Million |
| 2010 | -22.05% | -6.51% | 0.41x | 8.20x | $-2.11 Million |
| 2011 | 0.00% | -1195.35% | 0.05x | 0.00x | $-17.61 Million |
| 2012 | -91.89% | -837.82% | 0.04x | 3.03x | $-10.22 Million |
| 2013 | -728.75% | -3082.60% | 0.02x | 9.57x | $-31.25 Million |
| 2014 | 0.00% | -3402.60% | 0.06x | 0.00x | $-31.40 Million |
| 2015 | 930.79% | 97.99% | 1.95x | 4.87x | $6.16 Million |
| 2016 | -51.52% | -1860.89% | 0.02x | 1.14x | $-23.58 Million |
| 2017 | -22.54% | -3086.89% | 0.01x | 1.18x | $-23.80 Million |
| 2018 | -15.29% | -1635.38% | 0.01x | 1.12x | $-19.34 Million |
| 2019 | -14.45% | -439.36% | 0.03x | 1.13x | $-19.04 Million |
| 2020 | -13.62% | -285.22% | 0.04x | 1.12x | $-19.98 Million |
| 2021 | -9.80% | -54.59% | 0.15x | 1.19x | $-15.24 Million |
| 2022 | -21.20% | -81.15% | 0.22x | 1.20x | $-21.48 Million |
| 2023 | -24.20% | -40.90% | 0.47x | 1.26x | $-19.40 Million |
| 2024 | -6.33% | -4.92% | 0.89x | 1.44x | $-9.59 Million |
Industry Comparison
This section compares Kuros Biosciences AG's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kuros Biosciences AG (CSBTF) | $76.65 Million | -29.75% | 0.43x | $594.01 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |